Advertisement

Practical Applications of Intravenous Diuretic Therapy in Decompensated Heart Failure

      Abstract

      Intravenous (IV) loop diuretics play an important role in the treatment of decompensated heart failure (DHF). They inhibit the Na+-K+-2Cl reabsorptive pump in the thick ascending limb of the loop of Henle, and the resultant natriuresis and diuresis decreases volume load, improves hemodynamics, and reduces DHF symptoms. However, loop diuretics have a short half-life and their efficacy may be limited by postdiuretic sodium rebound during the period between doses in which the tubular diuretic concentration is subtherapeutic. Moreover, they can produce electrolyte abnormalities, neurohormonal activation, intravascular volume depletion, and renal dysfunction. Several studies have reported an association between diuretic therapy and increased morbidity and mortality. In addition, many patients, especially those with more advanced forms of heart failure (HF), are resistant to standard doses of loop diuretics. These high-risk, resistant patients may benefit from pharmacologic and/or nonpharmacologic interventions to improve hemodynamic performance, treatment of renovascular disease, discontinuation of aspirin and other sodium-retaining drugs, manipulation of the route of delivery or combination of diuretic classes, or hemofiltration. Despite >50 years of use, many questions regarding the use of intravenous diuretic agents in patients with DHF are still unanswered, and there remains a compelling need for well-designed randomized, controlled clinical trials to establish appropriate treatment regimens that maximize therapeutic benefit while minimizing morbidity and mortality.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fonarow G.C.
        Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry.
        Heart Failure Reviews. 2004; 9: 179-185
        • Cleland J.G.F.
        • Swedberg K.
        • Follath F.
        • et al.
        The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe.
        Eur Heart J. 2003; 24: 442-463
        • Cleland J.G.
        • Lalukota K.
        • Seymour A.
        Calcium sensitizers in acute heart failure.
        in: O’Connor C.M. Gattis S.W. Gheorghiade M. Adams K.F. Management of Acute Decompensated Heart Failure. Taylor & Francis CRC Press, Boca Raton, FL2005: 479-496
        • Nieminen M.S.
        • Böhm M.
        • Cowie M.R.
        • et al.
        • ESC Committee for Practice Guidelines (CPG)
        Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.
        Eur Heart J. 2005; 26: 384-416
        • DiDomenico R.J.
        • Park H.Y.
        • Southworth M.R.
        • et al.
        Guidelines for acute decompensated heart failure treatment.
        Ann Pharmacother. 2004; 38: 649-660
        • Gupta S.
        • Neyses L.
        Diuretic usage in heart failure: a continuing conundrum in 2005.
        Eur Heart J. 2005; 26: 644-649
        • Sackner-Bernstein J.D.
        Management of diuretic-refractory, volume-overloaded patients with acutely decompensated heart failure.
        Curr Cardiol Rep. 2005; 7: 204-210
        • Cody R.J.
        Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations.
        J Am Coll Cardiol. 1993; 22: 165A-171A
        • Hutton I.
        • McGhie A.I.
        • Martin W.
        • Tweddel A.C.
        A comparison of intravenous elantan and frusemide in patients with chronic cardiac failure.
        Cardiology. 1987; 74: 65-68
        • Verma S.P.
        • Silke B.
        • Hussain M.
        • et al.
        First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function.
        J Cardiovasc Pharmacol. 1987; 10: 38-46
        • Cotter G.
        • Metzkor E.
        • Kaluski E.
        • et al.
        Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema.
        Lancet. 1998; 351: 389-393
        • Brater D.C.
        Pharmacology of diuretics.
        Am J Med Sci. 2000; 319: 38-50
        • Ellison D.H.
        Diuretic resistance: physiology and therapeutics.
        Semin Nephrol. 1999; 19: 581-597
      1. Dickstein K. EuroHeart Survey: changes in the management of heart failure from 2000 to 2005. EuroHeart Survey on Heart Failure I vs EuroHeart Survey on Heart Failure II. Available at: http://www.escar-dio.org/NR/rdonlyres/AF261B82-E3D2-49AC-B6B7-BA82D26C9EDC/0/Dickstein_FP2546.pdf. Accessed December 20, 2005.

        • Dixon D.W.
        • Barwolf-Gohlke C.
        • Gunnar R.M.
        Comparative efficacy and safety of bumetanide and furosemide in long-term treatment of edema due to congestive heart failure.
        J Clin Pharmacol. 1981; 21: 680-687
        • Follath F.
        Do diuretics differ in terms of clinical outcome in congestive heart failure?.
        Eur Heart J. 1998; 19: P5-P8
        • Shankar S.S.
        • Brater D.C.
        Loop diuretics: from the Na-K-2Cl transporter to clinical use.
        Am J Physiol Renal Physiol. 2003; 284: F11-F21
        • Stroobandt R.
        • Dodion L.
        • Kesteloot H.
        Clinical efficacy of torasemide, a new diuretic agent, in patients with acute heart failure: a double blind comparison with furosemide.
        Arch Int Pharmacodyn Ther. 1982; 260: 151-158
        • Vargo D.L.
        • Kramer W.G.
        • Black P.K.
        • Smith W.B.
        • Serpas T.
        • Brater D.C.
        Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
        Clin Pharmacol Ther. 1995; 57: 601-609
        • Brater D.C.
        Diuretic therapy.
        N Engl J Med. 1998; 339: 387-395
        • Ellison D.H.
        Diuretic therapy and resistance in congestive heart failure.
        Cardiology. 2001; 96: 132-143
        • Kidney Disease Outcomes Quality Initiative (K/DOQI)
        K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.
        Am J Kidney Dis. 2004; 43: S1-S290
        • Krämer B.K.
        • Schweda F.
        • Riegger G.A.J.
        Diuretic treatment and diuretic resistance in heart failure.
        Am J Med. 1999; 106: 90-96
        • De Pasquale C.G.
        • Dunne J.S.
        • Minson R.B.
        • Arnolda L.F.
        Hypotension is associated with diuretic resistance in severe chronic heart failure, independent of renal function.
        Eur J Heart Fail. 2005; 7: 888-891
        • Lesch M.
        • Caranasos G.J.
        • Mulholland J.H.
        Controlled study comparing ethacrynic acid to mercaptomerin in the treatment of acute pulmonary edema.
        N Engl J Med. 1968; 279: 115-122
        • Cotter G.
        • Weissgarten J.
        • Metzkor E.
        • et al.
        Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure.
        Clin Pharmacol Ther. 1997; 62: 187-193
        • Wilcox C.S.
        • Mitch W.E.
        • Kelly R.A.
        • et al.
        Response of the kidney to furosemide. I. Effects of salt intake and renal compensation.
        J Lab Clin Med. 1983; 102: 450-458
        • Hariman R.J.
        • Bremner S.
        • Louie E.K.
        • et al.
        Dose-response study of intravenous torsemide in congestive heart failure.
        Am Heart J. 1994; 128: 352-357
        • Sagar S.
        • Sharma B.K.
        • Sharma P.L.
        • Wahi P.L.
        A comparative randomized double-blind clinical trial of bumetanide and furosemide in congestive cardiac failure and other edema states.
        Int J Clin Pharmacol Ther Toxicol. 1984; 22: 473-478
        • Lahav M.
        • Regev A.
        • Ra’anani P.
        • Theodor E.
        Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure.
        Chest. 1992; 102: 725-731
        • Brater D.C.
        Resistance to loop diuretics: why it happens and what to do about it.
        Drugs. 1985; 30: 427-443
        • Marsh J.D.
        • Nesto R.
        • Glynn M.A.
        • Smith T.W.
        Comparison of intravenous piretanide and furosemide in patients with congestive heart failure.
        J Cardiovasc Pharmacol. 1982; 4: 949-954
        • Cooper H.A.
        • Dries D.L.
        • Davis C.E.
        • Shen Y.L.
        • Domanski M.J.
        Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction.
        Circulation. 1999; 100: 1311-1315
        • Weber K.T.
        Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain.
        J Am Coll Cardiol. 2004; 44: 1308-1310
        • Butler J.
        • Forman D.E.
        • Abraham W.T.
        • et al.
        Relationship between heart failure treatment and development of worsening renal function among hospitalized patients.
        Am Heart J. 2004; 147: 331-338
        • Dormans T.P.J.
        • van Meyel J.J.M.
        • Gerlag P.G.G.
        • Tan Y.
        • Russel F.G.M.
        • Smits P.
        Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion.
        J Am Coll Cardiol. 1996; 28: 376-382
        • Gottlieb S.S.
        • Brater D.C.
        • Thomas I.
        • et al.
        BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy.
        Circulation. 2002; 105: 1348-1353
        • Schuller D.
        • Lynch J.P.
        • Fine D.
        Protocol-guided diuretic management: comparison of furosemide by continuous infusion and intermittent bolus.
        Crit Care Med. 1997; 25: 1969-1975
        • Agostoni P.
        • Marenzi G.
        • Lauri G.
        • et al.
        Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result.
        Am J Med. 1994; 96: 191-199
        • Bayliss J.
        • Norell M.
        • Canepa-Anson R.
        • Sutton G.
        • Poole-Wilson P.
        Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.
        Br Heart J. 1987; 57: 17-22
        • Costello-Boerrigter L.C.
        • Boerrigter G.
        • Burnett Jr., J.C.
        Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics.
        Med Clin North Am. 2003; 87: 475-491
        • Ikram H.
        • Chan W.
        • Espiner E.A.
        • Nicholls M.G.
        Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure.
        Clin Sci. 1980; 59: 443-449
        • Kubo S.H.
        • Clark M.
        • Laragh J.H.
        • Borer J.S.
        • Cody R.J.
        Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics.
        Am J Cardiol. 1987; 60: 1322-1328
        • Francis G.S.
        • Siegel R.M.
        • Goldsmith S.R.
        • Olivari M.T.
        • Levine T.B.
        • Cohn J.N.
        Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis.
        Ann Intern Med. 1985; 103: 1-6
        • Cleland J.G.
        • Gillen G.
        • Dargie H.J.
        The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure.
        Eur Heart J. 1988; 9: 132-141
        • Emerman C.L.
        • DeMarco T.
        • Costanzo M.R.
        • Peacock W.F.
        Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE Registry.
        J Card Fail. 2004; 10 (Abstract 368): S116
        • Mehta R.L.
        • Pascual M.T.
        • Soroko S.
        • Chertow G.M.
        • PICARD Study Group
        Diuretics, mortality, and nonrecovery of renal function in acute renal failure.
        JAMA. 2002; 288: 2547-2553
        • Neuberg G.W.
        • Miller A.B.
        • O’Connor C.M.
        • et al.
        • PRAISE Investigators
        Diuretic resistance predicts mortality in patients with advanced heart failure.
        Am Heart J. 2002; 144: 31-38
        • de Silva R.
        • Nikitin N.P.
        • Witte K.K.
        • et al.
        Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis.
        Eur Heart J. 2006; 27: 569-581
        • Philbin E.F.
        • Cotto M.
        • Rocco Jr, T.A.
        • Jenkins P.L.
        Association between diuretic use, clinical response, and death in acute heart failure.
        Am J Cardiol. 1997; 80: 519-522
        • Bakris G.L.
        • Weir M.R.
        Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?.
        Arch Intern Med. 2000; 160: 685-693
        • Brenner B.M.
        • Cooper M.E.
        • de Zeeuw D.
        • et al.
        • RENAAL Study Investigators
        Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
        N Engl J Med. 2001; 345: 861-869
        • CONSENSUS Trial Study Group
        Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
        N Engl J Med. 1987; 316: 1429-1435
        • Granger C.B.
        • McMurray J.J.
        • Yusuf S.
        • et al.
        • CHARM Investigators and Committees
        Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
        Lancet. 2003; 362: 772-776
        • Yusuf S.
        • Sleight P.
        • Pogue J.
        • et al.
        Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
        N Engl J Med. 2000; 342: 145-153
        • de Silva R.
        • Nikitin N.P.
        • Bhandari S.
        • Nicholson A.
        • Clark A.L.
        • Cleland J.G.
        Atherosclerotic renovascular disease in chronic heart failure: should we intervene?.
        Eur Heart J. 2005; 26: 1596-1605
        • MacDowall P.
        • Kalra P.A.
        • O’Donoghue D.J.
        • Waldek S.
        • Mamtora H.
        • Brown K.
        Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure.
        Lancet. 1998; 352: 13-16
        • Pickering T.G.
        • Herman L.
        • Devereux R.B.
        • et al.
        Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: treatment by angioplasty or surgical revascularisation.
        Lancet. 1988; 2: 551-552
        • Gray B.H.
        • Olin J.W.
        • Childs M.B.
        • Sullivan T.M.
        • Bacharach J.M.
        Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure.
        Vasc Med. 2002; 7: 275-279
        • Kennedy D.J.
        • Colyer W.R.
        • Brewster P.S.
        • et al.
        Renal insufficiency as a predictor of adverse events and mortality after renal artery stent placement.
        Am J Kidney Dis. 2003; 42: 926-935
        • Wheatley K.
        ASTRAL—the story so far.
        Journal of Renovascular Disease. 2003; 2: 1-2
        • Dikshit K.
        • Vyden J.K.
        • Forrester J.S.
        • Chatterjee K.
        • Prakash R.
        • Swan H.J.C.
        Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction.
        N Engl J Med. 1973; 288: 1087-1090
        • Johnston G.D.
        • Hiatt W.R.
        • Nies A.S.
        • Payne N.A.
        • Murphy R.C.
        • Gerber J.G.
        Factors modifying the early nondiuretic vascular effects of furosemide in man: the possible role of renal prostaglandins.
        Circ Res. 1983; 53: 630-635
        • Jhund P.S.
        • Davie A.P.
        • McMurray J.J.
        Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure.
        J Am Coll Cardiol. 2001; 37: 1234-1238
        • Pickkers P.
        • Dormans T.P.
        • Russel F.G.
        • et al.
        Direct vascular effects of furosemide in humans.
        Circulation. 1997; 96: 1847-1852
        • Juhlin T.
        • Björkman S.
        • Gunnarsson B.
        • Fyge Å
        • Roth B.
        • Höglund P.
        Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors.
        Eur J Heart Fail. 2004; 6: 909-916
        • Cleland J.G.
        • Ghosh J.
        • Freemantle N.
        • et al.
        Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure.
        Eur J Heart Fail. 2004; 6: 501-508
        • Cleland J.G.
        • Findlay I.
        • Jafri S.
        • et al.
        The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure.
        Am Heart J. 2004; 148: 157-164
        • Nesto R.W.
        • Bell D.
        • Bonow R.O.
        • et al.
        Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.
        Diabetes Care. 2004; 27: 256-263
        • Yelton S.L.
        • Gaylor M.A.
        • Murray K.M.
        The role of continuous infusion loop diuretics.
        Ann Pharmacother. 1995; 29: 1010-1014
        • Aaser E.
        • Gullestad L.
        • Tollofsrud S.
        • et al.
        Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure.
        Scand J Clin Lab Invest. 1997; 57: 361-367
        • Mojtahedzadeh M.
        • Salehifar E.
        • Vazin A.
        • et al.
        Comparison of hemodynamic and biochemical effects of furosemide by continuous infusion and intermittent bolus in critically ill patients.
        J Infus Nurs. 2004; 27: 255-261
        • Kramer W.G.
        • Smith W.B.
        • Ferguson J.
        • et al.
        Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure.
        J Clin Pharmacol. 1996; 36: 265-270
        • McBride B.F.
        • White C.M.
        Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management.
        Pharmacotherapy. 2003; 23: 997-1020
        • Pivac N.
        • Rumboldt Z.
        • Sardelic S.
        • et al.
        Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure.
        Int J Clin Pharmacol Res. 1998; 18: 121-128
        • Salvador D.R.
        • Rey N.R.
        • Ramos G.C.
        • Punzalan F.E.
        Continuous infusion versus bolus injection of loop diuretics in congestive heart failure.
        Cochrane Database Syst Rev. 2004; 1: CD003178
        • van Meyel J.J.
        • Smits P.
        • Dormans T.
        • Gerlag P.G.
        • Russel F.G.
        • Gribnau F.W.
        Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance.
        J Intern Med. 1994; 235: 329-334
        • Channer K.S.
        • McLean K.A.
        • Lawson-Matthew P.
        • Richardson M.
        Combination diuretic treatment in severe heart failure: a randomised controlled trial.
        Br Heart J. 1994; 71: 146-150
        • Dormans T.P.
        • Gerlag P.G.
        • Russel F.G.
        • Smits P.
        Combination diuretic therapy in severe congestive heart failure.
        Drugs. 1998; 55: 165-172
        • Kiyingi A.
        • Field M.J.
        • Pawsey C.C.
        • Yiannikas J.
        • Lawrence J.R.
        • Arter W.J.
        Metolazone in treatment of severe refractory congestive cardiac failure.
        Lancet. 1990; 335: 29-31
        • Sica D.A.
        • Gehr T.W.
        Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships.
        Clin Pharmacokinet. 1996; 30: 229-249
        • Sigurd B.
        • Olesen K.H.
        • Wennevold A.
        The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure: permutation trial tests in patients in long-term treatment with bumetanide.
        Am Heart J. 1975; 89: 163-170
        • Stewart J.H.
        • Edwards K.D.
        Clinical comparison of frusemide with bendrofluazide, mersalyl, and ethacrynic acid.
        BMJ. 1965; 5473: 1277-1281
        • van Vliet A.A.
        • Donker A.J.
        • Nauta J.J.
        • Verheugt F.W.
        Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.
        Am J Cardiol. 1993; 71: 21A-28A
        • Agostoni P.G.
        • Marenzi G.C.
        • Pepi M.
        • et al.
        Isolated ultrafiltration in moderate congestive heart failure.
        J Am Coll Cardiol. 1993; 21: 424-431
        • Marenzi G.
        • Lauri G.
        • Grazi M.
        • Assanelli E.
        • Campodonico J.
        • Agostoni P.
        Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure.
        J Am Coll Cardiol. 2001; 38: 963-968
        • Costanzo M.R.
        • Saltzberg M.
        • O’Sullivan J.
        • Sobotka P.
        Early ultrafiltration in patients with decompensated heart failure and diuretic resistance.
        J Am Coll Cardiol. 2005; 46: 2047-2051
        • Bart B.A.
        • Boyle A.
        • Bank A.J.
        • et al.
        Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) Trial.
        J Am Coll Cardiol. 2005; 46: 2043-2046
        • Dormans T.P.
        • Huige R.M.
        • Gerlag P.G.
        Chronic intermittent haemofiltration and haemodialysis in end stage chronic heart failure with oedema refractory to high dose frusemide.
        Heart. 1996; 75: 349-351